An interventional study of Ketum and Placebo in Pain, sponsored by Universiti Sains Malaysia. Status unknown at 1 site in Malaysia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-28.
Sponsored by Universiti Sains Malaysia · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Pain with a site in Malaysia — 2 open to participants now, 2 under way, none of them phase 3. Pain · Malaysia.
Among the 16 studies in Pain with a site in Malaysia, this one is the 15th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2018, is one of 13 with no phase, and was the 3rd registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →2 of the 16 studies in Pain with a site in Malaysia are open now. Recruiting first, the newest first:
International Islamic University Malaysia · Sites in Malaysia
Ages 15+
ROA RAAD FADHEL · Sites in Malaysia
Ages 18–33 · Women only
A study can be open while its sites in Malaysia have not opened yet or have stopped. Only those recruiting at a site in Malaysia →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 60 across the 15 interventional studies, 250 across the 1 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 16 has an industry lead sponsor. The 10 most frequent:
Universiti Sains Malaysia is the lead sponsor of 177 studies on the registry; 51 are open to participants now.
Universiti Sains Malaysia has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Pain with a site in Malaysia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07039071International Islamic University MalaysiaEvaluation of Clinical and Patient-Reported Outcomes of Laceback | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Pain with a site in Malaysia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aim is to evaluate potential analgesic properties of ketum using the cold pressor task.
Participants in the proposed study will be individuals who report consuming ketum more than once a day, daily for the past 12 months. The study is a placebo-controlled, double-blind within-subject repeated mesaures design. Participants will ingest a sequence of ketum and placebo drinks prepared by pharmacologists at USM Centre for Drug Research and their pain tolerance will be measured by the cold pressor task after ingesting ketum or placebo.
Inclusion Criteria: Individuals who report drinking ketum decoction more than once a day, daily for the past 12 months.
-
Exclusion Criteria: (1) tested positive for illicit drug use including morphine, cannabis, methamphetamine, amphetamine, methadone, benzodiazepine and ketamine; (2) have current or previous history of psychological or neurological problems (self-report); (3) have current or previous alcohol use history (self-report); (4) infections; (5) history of chronic liver disease (e.g. cirrhosis, hepatitis A, B, C, etc.) 6) non-alcoholic fatty liver disease; (7) history of coronary heart disease and diabetes; (8) existing chronic pain condition and (9) history of psychiatric disorders. Exclusion criteria for female particiapns: (1) pregnancy, (2) nursing.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each participant will consume a sequence of active ketum or placebo drinks. Pain tolerance will be measured using the cold pressor task after consuming each drink.
Drug: Ketum
Each participant will consume a sequence of active ketum or placebo drinks. Pain tolerance will be measured using the cold pressor task after consuming each drink.
Drug: Placebo
Ketum (Mitragyna speciosa) is an indigenous plant of Southeast Asia reported to have medicinal value in traditional culture
Also known as: Kratom
Placebo drink matched for taste and appereance
Pain tolerance
The duration (seconds) participants can keep their hands immersed in the water bath
Time frame: 3 hours
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2018 (actual). Primary completion is estimated for Dec 2021, 47 months after the start.
Of 3,740 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 47 months is above that.
Counting every sponsor, half of 3,839 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mitragyna speciosa leaf